Deakin University
Browse

File(s) not publicly available

Rebaudioside A loaded poly-d,l-lactide-nanoparticles as an anti-diabetic nanomedicine

Version 2 2024-06-13, 08:55
Version 1 2015-05-06, 10:25
journal contribution
posted on 2024-06-13, 08:55 authored by I Barwal, SC Yadav
Rebaudioside A is a major constituent (20% w/w) of natural stevioside powder and possess strong insulinotropic (anti-diabetic) activity with an extra glucose molecule than stevioside. In this manuscript, we have reported the nanofabrication of pure rebaudioside A and its effect on size, encapsulation efficiency and in vitro release. These results have been compared with stevioside nanoparticles using same synthesis process to evaluate the effect of extra glycosylation on nanoencapsulation (Colloids and surfaces B: Biointerfaces, 101 (2013) 510-516). Mono-disperse rebaudioside A-PLA nanoparticles of larger size (150-200 nm) than stevioside NPs (110-130 nm) were obtained along with 28.57% molecular loading efficiency (w/w%). However, rebaudioside A-PLA nanoparticle shows similar in vitro burst and sustained release upto 200 h as nano-stevioside. This study reveals that rebaudioside A-PLA nanoparticles can be used as a better antidiabetic nanomedicine than previously reported stevioside PLA nanoparticles.

History

Journal

Journal of bionanoscience

Volume

8

Pagination

137-140

Location

Valencia, Calif.

ISSN

1557-7910

eISSN

1557-7929

Language

eng

Publication classification

C1.1 Refereed article in a scholarly journal

Copyright notice

2014, American Scientific Publishers

Issue

2

Publisher

American Scientific Publishers

Usage metrics

    Research Publications

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC